CCR4 and neoplasm: This was demonstrated by Watanabe et al. [187], who showed that their CCR4 CAR-T product is enriched in Th1 cells due to fratricide of Th2 and Treg cells, possibly yielding improved anti-tumor efficacy and engraftment compared to CD19 CAR-T cells.